Blocking a Single Enzyme Reverses Age-Related Muscle Loss in Mice
Inhibiting glutaminase (GLS1) with CB-839 restores mitochondrial function and rebuilds muscle strength in aging models.
Summary
As muscles age, they lose mass and strength — a condition called sarcopenia. Researchers at the University at Buffalo discovered that a key driver may be an enzyme called glutaminase (GLS1), which becomes overactive in aging muscle cells. This overactivity causes urea to build up inside cells, damaging the mitochondria — the energy-producing structures that keep muscles functioning. When scientists blocked GLS1 with a drug called CB-839, urea levels dropped, mitochondrial function was restored, and energy-generating machinery recovered. In aging mice, the same drug improved muscle structure and physical strength. These findings point to glutamine metabolism as an underappreciated but potentially targetable pathway in sarcopenia — and CB-839, already studied in cancer trials, as a candidate drug worth exploring for muscle aging.
Detailed Summary
Sarcopenia — the progressive loss of skeletal muscle mass and function with age — is one of the most consequential drivers of frailty, falls, and loss of independence in older adults. Despite its prevalence, few pharmacological options exist. This study from the University at Buffalo identifies a novel and potentially druggable mechanism connecting aging muscle cells to mitochondrial failure.
The researchers found that senescent skeletal muscle myoblasts — aged, dysfunctional muscle precursor cells — show markedly elevated activity and expression of glutaminase 1 (GLS1), an enzyme that converts glutamine into glutamate. This upregulation is controlled by p38 MAPK signaling, a stress pathway known to be active in aging cells. The abnormal GLS1 activity leads to intracellular urea accumulation, which the team identified as a direct impairment to mitochondrial function — specifically disrupting the electron transport chain (ETC) complexes responsible for cellular energy production.
Pharmacological inhibition of GLS1 using CB-839 — a drug already in human clinical trials for cancer — reversed these effects in cell culture. Urea levels normalized, ETC complex expression was restored, and mitochondrial respiration improved. Critically, these findings translated to an animal model: progeroid mice treated with CB-839 showed upregulated ETC complexes, enhanced mitochondrial respiratory capacity, better muscle structural integrity, and measurably greater muscle strength.
The implications are significant. This work adds glutamine metabolism to the growing list of metabolic pathways implicated in muscle aging, and suggests that GLS1 inhibition could be a viable therapeutic strategy to slow or even partially reverse sarcopenia by targeting its mitochondrial root cause.
Caveats apply. The in vivo work used progeroid mice — a genetic model of accelerated aging — which may not fully replicate normal human aging. CB-839's safety and efficacy in older human populations for this indication are unknown. Full-text details on dosing, study duration, and control conditions are unavailable, as this summary is based on the abstract only.
Key Findings
- Senescent muscle cells overexpress GLS1 via p38 MAPK signaling, causing urea accumulation that impairs mitochondrial function.
- CB-839 (a GLS1 inhibitor) reduced intracellular urea and restored electron transport chain complexes in aged muscle cells.
- Progeroid mice treated with CB-839 showed improved mitochondrial respiration, muscle structure, and physical strength.
- Targeting glutamine metabolism represents a new pharmacological approach to sarcopenia beyond current options.
- CB-839 is already in human cancer trials, potentially accelerating its evaluation for muscle aging indications.
Methodology
The study used senescent human skeletal muscle myoblasts to characterize GLS1 activity and urea accumulation in vitro, then applied CB-839 to assess mitochondrial rescue. In vivo validation was conducted in progeroid mice, measuring ETC complex expression, mitochondrial respiratory capacity, muscle structural integrity, and muscle strength.
Study Limitations
This summary is based on the abstract only; full methodology, dosing details, and control conditions are unavailable. The animal model uses progeroid (accelerated aging) mice, which may not perfectly represent normal human aging biology. CB-839's therapeutic window, optimal dosing, and safety profile in elderly populations for this indication remain to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: